Emerging treatments in chronic hepatitis B

Expert Opinion on Emerging Drugs

Volumn 9, Issue 2, 2004, Pages 207-221

  Hadziyannis, Stephanos J ^a   Papatheodoridis, George V ^b  

^a HENRY DUNANT HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Adefovir; Chronic hepatitis B; Combination therapy; Entecavir; Hepatitis B virus; IFN ; Lamivudine; Nucleoside analogues; Pegylated IFN ; Thymosin

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; CLEVUDINE; ELVUCITABINE; EMTRICITABINE; ENTECAVIR; FAMCICLOVIR; FIALURIDINE; GAMMA INTERFERON; GANCICLOVIR; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; MONOCLONAL ANTIBODY; NUCLEOSIDE ANALOG; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; TELBIVUDINE; TENOFOVIR; THYMOSIN; THYMOSIN ALPHA1; TORCITABINE; VALTORCITABINE;

ABDOMINAL PAIN; BONE MARROW SUPPRESSION; CHRONIC HEPATITIS; DEPRESSION; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FLU LIKE SYNDROME; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNIZATION; INCIDENCE; IRRITABILITY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LONG TERM CARE; MONOTHERAPY; MORBIDITY; MORTALITY; REVIEW; RHINITIS; SEROCONVERSION; SERODIAGNOSIS; SYSTEMATIC REVIEW; VIRUS RESISTANCE; WORLD HEALTH ORGANIZATION;

ADENINE; ANTIVIRAL AGENTS; CLINICAL TRIALS; DRUG COMBINATIONS; DRUG RESISTANCE, VIRAL; DRUG THERAPY; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON-ALPHA; LAMIVUDINE; PHOSPHONIC ACIDS; VACCINES;

EID: 10344235972     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.9.2.207     Document Type: Review

References (161)

1. KANE M: Global programme for control of hepatitis B infection. Vaccine (1995) 13:S47-S49.
2. GAY N, EDMUNDS W, BAH E, NELSON C: Estimating the global burden of hepatitis B. Geneva: World Health Organization. Department of Vaccines and Biologicals (2001).
3. LEE WM: Hepatitis B virus infection. N. Engl. J. Med. (1997) 337:1733-1745.
4. LIAW YF, TAI DI, CHU CM, CHEN TJ: The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology (1988) 8:493-496.
5. FATTOVICH G, BROLLO L, GIUSTINA G et al.: Natural-history and prognostic factors for chronic hepatitis type B. Gut (1991) 32:294-298.
6. WEISSBERG JI, ANDRES LL, SMITH CI et al.: Survival in chronic hepatitis B. An analysis of 379 patients. Ann. Intern. Med. (1984) 101:613-616.
7. DE JONGH FE, JANSSEN HLA, DE MAN RA, HOP WCJ, SCHALM SW, VAN BLANKENSTEIN M: Survival and prognostic indicators in HBsAg-positive cirrhosis of the liver. Gastroenterology (1992) 103:1630-1635.
8. REALDI G, FATTOVICH G, HADZIYANNIS S et al.: Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. J. Hepatol. (1994) 21:656-666.
9. BEASLEY RP: The major etiology of hepatocellular carcinoma. Cancer (1988) 61:1942-1956.
10. PARKIN DM, BRAY F, FERLAY J, PISANI P: Estimating the world cancer burden: Globocan 2000. Int. J. Cancer (2001) 94:153-156.
11. EASL International consensus conference on hepatitis B. J. Hepatol. (2003) 39(Suppl. 1):S3-S25. This review provides the summary of an international consensus conference on hepatitis B sponsored by EASL and held in September 2002.
12. LOK AS, HEATHCOTE EJ, HOOFNAGLE JH: Management of hepatitis B: 2000-summary of a workshop. Gastroenterology (2001) 120:1828-1853. This review provides the summary of a 3-day workshop on the management of hepatitis B sponsored by the NIDDK and AGA and held in September 2000.
13. HADZIYANNIS SJ, VASSILOPOULOS D: Hepatitis B e antigen-negative chronic hepatitis B. Hepatology (2001) 34:617-624. A review focused on the pathogenesis of HBeAg-negative chronic hepatitis B.
14. LOK ASE MCMAHON BJ: Chronic hepatitis B. Hepatology (2001) 34:1225-1241.
15. HOOFNAGLE JH, DUSHEIKO GM, SEEFF LB, JONES A, WAGGONER JG, BALES ZB: Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann. Intern. Med. (1981) 94:744-748.
16. FATTOVIC HG, RUGGE M, BROLLO L et al.: Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology (1986) 6:167-172.
17. YANG H-I, LU S-N, LIAW Y-F et al.: Hepatitis B e antigen and the risk of hepatocellular carcinoma. N. Engl. J. Med. (2002) 347:168-174.
18. HADZIYANNIS SJ: Hepatitis B e antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Vir. Hep. Rev. (1995) 1:7-36.
19. HUNT CM, MCGILL JM, ALLEN ML, CONDREAY LD: Clinical relevance of hepatitis B virus mutations. Hepatology (2000) 31:1037-1044.
20. BONINO F, ROSINA F, RIZZETTO M et al.: Chronic hepatitis in HBsAg carriers with serum HBV-DNA and anti-HBe. Gastroenterology (1986) 90:1268-1273.
21. BRUNETTO MR, GIARIN M, OLIVERI F et al.: Wild type and e antigenminus hepatitis B virus in course of chronic hepatitis. Prac. Natl. Acad. Sci. USA (1991) 88:4186-4190.
22. NAOUMOV NV, SCHNEIDER R, GROTZINGER T et al.: Precore mutant hepatitis B virus infection and liver disease. Gastroenterology (1992) 102:538-543.
23. LAI ME, SOLINAS A, MAZZOLENI AP et al.: The role of pre-core hepatitis B virus mutants on the long-term outcome of chronic hepatitis B virus hepatitis. A longitudinal study. J. Hepatol. (1994) 20:773-781.
24. WONG DKH, CHEUNG AM, O'ROURKE K, NAYLOR CD, DETSKY AS, HEATHCOTE J: Effect of alpha-interferon in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann. Intern. Med (1993) 119:312-323.
25. BROOK MG, KARAYIANNIS P, THOMAS HC: Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology (1989) 10:761-763.
26. PAPATHEODORIDIS GV, HADZIYANNIS SJ: Current management of chronic hepatitis B. Aliment. Pharmacol. Ther. (2004) 19:25-37. A review on the management of chronic hepatitis B in early 2004.
27. PAPATHEODORIDIS GV, HADZIYANNIS SJ: Diagnosis and management of pre-core mutant chronic hepatitis B. J. Viral Hepat. (2001) 8:311-321.
28. BRUNETTO MR, OLIVERI F, COLOMBATTO P, CAPALBO M, BARBERA C, BONINO F: Treatment of chronic anti-HBe-positive hepatitis B with interferon-alpha. J. Hepatol. (1995) 22:42-44.
29. HADZIYANNIS SJ, PAPATHEODORIDIS GV, VASSILOPOULOS D: Treatment of HBeAg-negative chronic hepatitis B. Semin. Liver Dis. (2003) 23:81-88. A review on the goals, indications and efficacy of therapeutic options for HBeAg-negative chronic hepatitis B in early 2003.
30. HADZIYANNIS SJ, PAPATHEODORIDIS GV: Treatment of HBeAg negative chronic hepatitis B with new drugs (adefovir and others). J. Hepatol. (2003) 39(Suppl. 1):S172-S176.
31. KARAYIANNIS P: Hepatitis B virus: old, new and future approaches to antiviral treatment. J. Antimicrob. Chemother. (2003) 51:761-785.
32. HOOFNAGLE JH, DI BISCEGLIE AM: The treatment of chronic viral hepatitis. N. Engl. J. Med. (1997) 336:347-356.
33. KORENMAN J, BAKER B, WAGGONEK J, EVERHART JE, DI BISCEGLIE AM, HOOFNAGLE JH: Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann. Intern. Med. (1991) 114:629-634.
34. NIEDERAU C, HEINTGES T, LANGE S et al.: Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N. Engl. J. Med. (1996) 334:1422-1427.
35. VAN NUNEN AB, HANSEN BE, SUH DJ et al.: Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut (2003) 52:420-424.
36. KAO J-H, WU N-H, CHEN P-J, LAI M-Y, CHEN D-S: Hepatitis B genotypes and the response to interferon therapy. J. Hepatol. (2000) 33:998-1002.
37. WAI CT, CHU C-J, HUSSAIN M, LOK ASF: HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology (2002) 36:1425-1430.
38. MANESIS EK, HADZIYANNIS SJ: Interferon-alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology (2001) 121:101-109. The largest study of standard interferon therapy in HBeAg-negative chronic hepatitis B.
39. LAMPERTICO P, DEL NINNO E, VIGANO M et al.: Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology (2003) 37:756-763.
40. ZHANG X, ZOULIM F, HABERSETZER F, XIONG S, TREPO C: Analysis of hepatitis B virus genotypes and pre-core region variability during interferon treatment of HBe antigen negative chronic hepatitis B. J. Med. Virol. (1996) 48:8-16.
41. ERHARDT A, REINEKE U, BLONDIN D et al.: Mutations in the core promoter and response to interferon treatment in chronic replicative hepatitis B. Hepatology (2000) 31:716-725.
42. CARRENO V, MARCELLIN P, HADZIYANNIS S et al.: Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa 2a. The European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology (1999) 30:277-282.
43. VINAYEK R, SHAKIL O: Adverse events associated with interferon-alfa therapy in patients with chronic viral hepatitis. Viral Hep. Rev. (1997) 3:167-177.
44. WONG JB, KOFF RS, TINE F, PAUKER SG: Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann. Intern. Med. (1995) 122:664-675.
45. JARVIS B, FAULDS D: Lamivudine. A review of its therapeutic potential in chronic hepatitis B. Drugs (1999) 58:101-141.
46. LAI C-L, CHIEN R-N, LEUNG NWY et al.: A one-year trial of lamivudine for chronic hepatitis B. N. Engl. J. Med. (1998) 339:61-68.
47. DIENSTAG JL, SCHIFF ER, WRIGHT TL et al.: Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. (1999) 341:1256-1263.
48. DIENSTAG JL, SCHIFF ER, MITCHELL M et al.: Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Hepatology (1999) 30:1082-1087.
49. SCHIFF E, CIANCIARA J, KARAYALCIN S et al.: Durable HBeAg and HBsAg seroconversion after lamivudine for chronic hepatitis B. J. Hepatol. (2000) 32(Suppl. 2):99.
50. CHANG TT, LAI CL, LIAW YF et al.: Incremental increases in HBeAg seroconversion and continued ALT normalisation in Asian chronic HBV (CHB) patients treated with lamivudine for four years. Antivir. Therapy (2000) 5(Suppl. 1):44.
51. SONG B-C, SUH DJ, LEE HC, CHUNG Y-H, LEE YS: Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology (2000) 32:803-806.
52. LEUNG NW, LIAW Y-F, CHANG T-T et al.: Durable HBeAg response in Chinese patients treated with lamivudine. Hepatology (2001) 34:348A.
53. LEUNG NWY, LAI CL, CHANG TT et al.: Three year lamivudine therapy in chronic HBV. J. Hepatol. (1999) 30(Suppl. 1):59.
54. LIAW Y-F, LEUNG NWY, CHANG T-T et al.: Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology (2000) 119:172-180.
55. TASSOPOULOS NC, VOLPES R, PASTORE G et al.: Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology (1999) 29:889-896.
56. HADZIYANNIS SJ, PAPATHEODORIDIS GV, DIMOU E, LARAS A, PAPAIOANNOU C: Efficacy of long-term lamivudine monotherapy in patients with HBeAg negative chronic hepatitis B. Hepatology (2000) 32:847-851.
57. PAPATHEODORIDIS GV, DIMOU E, LARAS A, PAPADIMITROPOULOS V, HADZIYANNIS SJ: Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology (2002) 36:219-226.
58. TASSOPOULOS NC, VOLPES R, PASTORE G et al.: Post lamivudine treatment follow up of patients with HBeAg negative chronic hepatitis B. J. Hepatol. (1999) 30(Suppl. 1):117.
59. SANTANTONIO T, MAZZOLA M, IACOVAZZI T, MIGLIETTA A, GUASTADISEGNI A, PASTORE G: Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J. Hepatol. (2000) 32:300-306.
60. DI MARCO V, MARZANO A, LAMPERTICO P et al.: The course of anti-HBe/HBV-DNA positive chronic liver disease during long-term lamivudine treatment. J. Hepatol. (2003) 38(Suppl. 2):25.
61. PAPATHEODORIDIS GV, DIMOU E, PAPADIMITROPOULOS V: Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance. Am. J. Gastroenterol. (2002) 97:1618-1628.
62. ALLEN MI, DESLAURIERS M, ANDREWS CW et al.: Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology (1998) 27:1670-1677.
63. LAU DTY, KHOKHAR MF, DOO E et al.: Long-term therapy of chronic hepatitis B with lamivudine. Hepatology (2000) 32:828-834.
64. DIENSTAG JL, GOLDIN RD, HEATHCOTE EJ et al.: Histologic outcome during long-term lamivudine therapy. Gastroenterology (2003) 124:105-117. An important study showing the effect of lamivudine-resistant HBV mutants on the liver histology of patients with HBeAg-positive chronic hepatitis B under long-term lamivudine therapy.
65. CUNDY KC: Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin. Pharmacokinet. (1999) 36:127-143.
66. HADZIYANNIS SJ, PAPATHEODORIDIS GV: Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection. Expert Rev. Anti-infect. Ther. (2004) 2:475-483.
67. KNIGHT W, HAYASHI S, BENHAMOU Y et al.: Dosing guidelines for adefovir dipivoxil in the treatment of HBV infected patients with renal or hepatic impairment. J. Hepatol. (2002) 36(Suppl. 1):136.
68. MARCELLIN P, CHANG TT, LIM SG et al.: Adefovir dipivoxil for the treatment of hepatitis B antigen-positive chronic hepatitis B. N. Engl. J. Med. (2003) 348:808-816. This randomised, multi-centre, placebo-controlled trial demonstrated the safety and efficacy of a 48-week course with adefovir dipivoxil in patients with HBeAg-positive chronic hepatitis B.
69. HEATHCOTE E, JEFFERS L, PERRILLO R et al.: Sustained antiviral response and lack of viral resistance with long term adefovir dipivoxil (ADV) therapy in chronic HBV infection. J. Hepatol. (2002) 36(Suppl. 1):110-111.
70. HADZIYANNIS SJ, TASSOPOULOS NC, HEATHCOTE EJ et al.: Adefovir dipivoxil for the treatment of hepatitis B antigen-negative chronic hepatitis B. N. Engl. J. Med (2003) 348:800-807. This randomised, multi-centre, double-blind, placebo-controlled trial demonstrated the safety and efficacy of a 48-week course with adefovir dipivoxil in patients with HBeAg-negative chronic hepatitis B.
71. HADZIYANNIS SJ, TASSOPOULOS N, HEATHCOTE E et al.: Two year results from a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for presumed precore mutant chronic hepatitis B. J. Hepatol. (2003) 38(Suppl. 2):143.
72. HADZIYANNIS SJ, TASSOPOULOS N, CHANG TT et al.: Three year study of adefovir dipivoxil (ADV) demonstrates sustained efficacy in presumed precore mutant chronic hepatitis B (CHB) patients in a long term safety and efficacy study (LTES).J. Hepatol. (2004) 40(Suppl. 1):17. This study, recently presented as an abstract, showed the safety and sustained efficacy of 3 years therapy with adefovir dipvoxil in patients with HBeAg-negative chronic hepatitis B.
73. XIONG S, YANG H, WESTLAND CE. et al.: Resistance surveillance of HBeAg-chronic hepatitis B (CHB) patients treated for two years with adefovir dipivoxil. (ADV). J. Hepatol. (2003) 38(Suppl. 2):182.
74. QI X, SNOW A, THIBAULT V et al.: Long-term incidence of adefovir dipivoxil (ADV) resistance in chronic hepatitis B (CHB) patients after 144 weeks of therapy. J. Hepatol. (2004) 40(Suppl. 1):20-21.
75. ANGUS P, VAUGHAN R, XIONG S et al.: Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology (2003) 125:292-297. The first study describing in detail the HBV mutations associated with resistance to adefovir dipivoxil.
76. ZOULIM F, TREPO C, POYNARD T et al.: Adefovir dipivoxil (ADV) for the treatment of patients with chronic hepatitis B (CHB) failing lamivudine (LAM) therapy. J. Hepatol. (2003) 38(Suppl. 2):184.
77. PETERS MG, HANN HH, MARTIN P et al.: Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology (2004) 126:91-101. A study showing that adefovir dipivoxil monotherapy may have the same efficacy with the combination of adefovir dipivoxil and lamivudine in the treatment of lamivudine-resistant patients with HBeAg-positive chronic hepatitis B.
78. WESTLAND CE, YANG H, NAMIMI H et al.: Comparison of anti-HBV activity of adefovir against different lamivudine-resistant HBV strains in vitro and in liver transplant patients. Hepatology (2001) 34:446A.
79. LEBRAY P, VALLET-PICHARD A, MICHEL ML et al.: Immunomodulatory drugs and therapeutic vaccine in chronic hepatitis B infection. J. Hepatol. (2003) 39(Suppl. 1): S151-S159.
80. KUHNS M, MCNAMARA A, MASON A, CAMPBELL C, PERRILLO R: Serum and liver hepatitis B virus DNA in chronic hepatitis B after sustained loss of surface antigen. Gastroenterology (1992) 103:1649-1656.
81. KOMORI M, YUKI N, NAGAOKA T et al.: Long-term clinical impact of occult hepatitis B virus infection in chronic hepatitis B patients. J. Hepatol. (2001) 35:798-804.
82. PAPATHEODORIDIS GV, MANESIS E, HADZIYANNIS SJ: The long-term outcome of interferon-α treated and untreated patients with HBeAg-negative chronic hepatitis B. J. Hepatol. (2001) 34:306-313. An important study showing the effect of the IFN therapy and particularly of the type of response to IFN therapy on the long-term outcome of patients with HBeAg-negative chronic hepatitis B.
83. NOWAK MA, BONHOEFFER S, HILL AM, BOEHME R, THOMAS HC, MCDADE H: Viral dynamics in hepatitis B virus infection. Proc. Natl. Acad. Sci. USA (1996) 93:4398-4402.
84. 2a. in HBeAg-positive chronic hepatitis B.
85. SUNG JJY, CHAN HLY, HUI AY et al.: Combination of pegylated interferon and lamivudine is superior to lamivudine monotherapy in the treatment of chronic hepatitis B - a randomized trial. J. Hepatol. (2003) 38(Suppl. 2):33.
86. 2a and lamivudine, both being superior than lamivudine alone.
87. TORRESI J, LOCARNINI S: Antiviral chemotherapy for the treatment of hepatitis B virus infections. Gastroenterology (2000) 118(Suppl.):S83-S103.
88. HART GJ, ORR DC, PENN CR et al.: Effects of (-)-2′-deoxy-3′- thiacytidine (3TC) 5′-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma. Antimicrob. Agents Chemother. (1992) 36:1688-1694.
89. TUTTLEMAN JS, POURCEL C, SUMMERS J: Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell (1986) 47:451-460.
90. MORALEDA G, SAPUTELLI J, ALDRICH CE, AVERETT D, CONDREAY L, MASON WS: Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the dosed circular DNA of woodchuck hepatitis virus. J. Virol. (1997) 71:9392-9399.
91. ARTS E, WAINBERG M: Mechanism of nudeoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription. Antimicrob. Agents Chemother. (1996) 40:527-540.
92. WERLE-LAPOSTOLLE B, BOWDEN S, LOCARNINI S et al.: Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology (2004) 126:1750-1758.
93. SHAW T, BOWDEN S, LOCARNINI S: Rescue therapy for drug resistant hepatitis B: another argument for combination chemotherapy? Gastroenterology (2004) 126:343-347.
94. NATIONAL INSTITUTE OF HEALTH CONSENSUS DEVELOPMENT CONFERENCE STATEMENT: Management of hepatitis C: 2002 - June 10-12, 2002. Hepatology (2002) 36(Suppl. 1):S3-S20. This review provides the summary of the consensus statement on the management of hepatitis C sponsored by the NIH and held in 2002.
95. VAN ZONNEVELD M, VAN NUNEN AB, DE MAN RA, SCHALM SW, JANSSEN HLA: Chronic HBV treatment with one year of pegylated-interferon alpha-2b (PEG-IFN) has a comparable safety profile to short term conventional interferon alpha-2b. J. Hepatol. (2003) 38(Suppl. 2):179.
96. VAN ZONNEVELD M, ZONDERVAN P, DE MAN RA, SCHALM SW, JANSSEN HLA: Liver histology in chronic hepatitis B patients after 1 year of treatment with pegylated interferon interferon alpha-2b in combination with lamivudine or placebo. J. Hepatol. (2004) 40 (Suppl. 1):132.
97. YAMANAKA G, WILSON T, INNAIMO S et al.: Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus. Antimicrob. Agents Chemother. (1999) 43:190-193.
98. NEVENS F, DE MAN RA, CHUA D et al.: Effectiveness of a low dose of entecavir in treating recurrent viremia in chronic hepatitis B. Hepatology (2000) 32(Suppl.):377A.
99. LAI C-L, ROSMAWATI M, LAO J et al.: Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B. Gastroenterology (2002) 123:1831-1838. An interesting study on the antiviral efficacy of entecavir.
100. DE MAN RA, WOLTERS L, NEVENS F et al.: A study of oral entecavir given for 28 days in both treatment-naive and pretreated subjects with chronic hepatitis. Hepatology (2000) 32(Suppl.):376A.
101. TASSOPOULOS N, HADZIYANNIS S, CIANCIARA J et al.: Entecavir is effective in treating patients with chronic hepatitis B who have failed lamivudine therapy. Hepatology (2001) 34:340A.
102. CHANG T-T, HADZIYANNIS S, CIANCIARA J et al.: Sustained viral load and ALT reduction following 48 weeks of entecavir treatment in subjects with chronic hepatitis B who have failed lamivudine. Hepatology (2002) 36:300A.
103. COLONNO R, ROSE R: Genotypic analysis following 48 week entecavir treatment of chronic HBV subjects failing lamivudine suggests sustained susceptibility and lack of resistance development. Hepatology (2002) 36:644A.
104. GISH R, CHANG TT, HADZIYANNIS S et al.: Sustained viral load and ALT reduction following 48 weeks of entecavir treatment in HBeAg-negative and -positive patients with chronic hepatitis B who have failed prior lamivudine therapy. J. Hepatol. (2003) 38(Suppl. 2):32-33.
105. KORBA BE, SCHINAZI RF, COTE P, TENNANT BC, GERIN JL: Effect of oral administration of emtricitabine on woodchuck hepatitis virus replication in chronically infected woodchucks. Antimicrob. Agents Chemother. (2000) 44:1757-1760.
106. LADNER SK, MILLER TJ, OTTO MJ, KING RW: The hepatitis B virus M539V polymerase variation responsible for 3TC resistance also confers cross-resistance to other nucleoside analogues. Antivir. Chem. Chemother. (1998) 9:65-72.
107. WANG C, CORREY L, LEUNG N et al.: Antiviral activitry of 48 weeks of emtricitabine (FTC) treatment in patients with HBeAg negative/HBV DNA positive chronic hepatitis B (CHB). Hepatology (2001) 34:323A.
108. CHU CK, MA T, SHANMUGANATHAN K et al.: Use of 2′-fluoro-5-methyl- beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus. Antimicrob. Agents Chemother. (1995) 39:979-981.
109. CHU CK, BOUDINOT FD, PEEK SF et al.: Preclinical investigation of L-FMAU as an anti-hepatitis B virus agent. Antivir. Ther. (1998) 3(Suppl. 3):113-121.
110. PEEK SF, COTE PJ, JACOB JR et al.: Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-beta, 1-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax). Hepatology (2001) 33:254-266.
111. ABDELHAMED AM, KELLEY CM, MILLER TG, FURMAN PA, CABLE EE, ISOM HC: Comparison of anti-hepatitis B virus activities of lamivudine and clevudine by a quantitative assay. Antimicrob. Agents Chemother. (2003) 47:324-336.
112. MARCELLIN P, MOMMEJA-MARIN H, SACKS SL et al.: A Phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. Hepatology (2004) 40:140-148. An interesting Phase II study on the antiviral efficacy of clevudine.
113. STANDRING DN, BRIDGES EG, PLACIDI L et al.: Antiviral beta-L-nucleosides specific for hepatitis B virus infection. Antivir. Chem. Chemother. (2003) 12(Suppl. 1):119-129. A review focusing on the L-nucleosides as new anti-HBV agents.
114. BRYANT ML, BRIDGES EG, PLACIDI L et al.: Antiviral L-nudeosides specific for hepatitis B virus infection. Antimicrob. Agents Chemother. (2001) 45:229-235.
115. DELANEY W, YANG H, MILLER M, GIBBS C, XIONG S: Lamivudine-resistant HBV is cross-resistant to L-dT and L-dC in vitro. J. Hepatol. (2002) 36(Suppl. 1):89.
116. HODGE RA: Telbivudine/torcitabine Idenix/Novartis. Curr. Opin. Investig. Drugs (2004) 5:232-241.
117. LAI C-L, MYERS MW, POW DM et al.: Safe and potent suppression of hepatitis B virus (HBV) with L-deoxythymidine (LDT): results of a dose-escalation trial. Hepatology (2001) 34:321A.
118. LAI C-L, LEUNG N, TEO EK et al.: International multicenter trial of LdT (telbivudine), alone and in combination with lamivudine, for chronic hepatitis B: an interim analysis. Hepatology (2002) 36:301A.
119. LAI C-L, LEUNG NWY, TEO E-K et al.: Results of a one-year international Phase IIb comparative trial of telbivudine, lamivudine, and the combination, in patients with chronic hepatitis B. Hepatology (2003) 38(Suppl. 1):262A.
120. BENHAMOU Y, POYNARD T: Treatment of chronic hepatitis B virus infection in patients co-infected with human immunodeficiency virus. J. Hepatol. (2003) 39(Suppl. 1):S194-S199.
121. LESSELLS R, LEEN C: Management of hepatitis B in patients coinfected with the human immunodeficiency virus. Eur. J. Clin. Microbiol. Infect. Dis. (2004) 23:366-374.
122. BENHAMOU Y: Antiretroviral therapy and HIV/hepatitis B virus coinfection. Clin. Infect. Dis. (2004) 38(Suppl. 2):S98-S103.
123. DORE GJ, COOPER DA, POZNIAK AL et al.: Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J. Infect. Dis. (2004) 189:1185-1192.
124. LERBAEK A, KRISTIANSEN TB, KATZENSTEIN TL et al.: Tenofovir treatment in an unselected cohort of highly antiretroviral experienced HIV positive patients. Scand. J. Infect. Dis. (2004) 36:280-286.
125. BENHAMOU Y, BOCHET M, THIBAULT V et al.: Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet (2001) 358:718-723.
126. BILLICH A: Thymosin alpha1. SciClone Pharmaceuticals. Curr. Opin. Investig. Drugs (2002) 3:698-707.
127. MUTCHNICK MG, APPELMAN HD, CHUNG HT et al.: Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial. Hepatology (1991) 14:409-415.
128. CHIEN RN, LIAW YF, CHEN TC, YEH CT, SHEEN IS: Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology (1998) 27:1383-1387.
129. MUTCHNICK MG, LINDSAY KL, SCHIFF ER et al.: Thymosin alphal treatment of chronic hepatitis B: results of a Phase III multicentre, randomized, double-blind and placebo-controlled study. J. Viral Hepat. (1999) 6:397-403.
130. ZAVAGLIA C, SEVERINI R, TINELLI C et al.: A randomized, controlled study of thymosin-alpha1 therapy in patients with anti-HBe, HBV-DNA-positive chronic hepatitis B. Dig. Dis. Sci. (2000) 45:690-696.
131. 1 versus interferon-alpha-treatment in patients with HBeAg negative and serum HBV DNA positive chronic hepatitis B. World J. Gastroenterol. (2001) 7:407-410.
132. 1 versus interferon-alpha in patients with hepatitis B. World J. Gastroenterol. (2001) 7:411-414.
133. ARASE Y, TSUBOTA A, SUZUKI Y et al.: A pilot study of thymosin alpha1 therapy for chronic hepatitis B patients. Intern. Med. (2003) 42:941-946.
134. ANDREONE P, CURSARO C, GRAMENZI A et al.: A randomized controlled trial of thymosin-alpha1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody-and hepatitis B virus DNA-positive chronic hepatitis B. Hepatology (1996) 24:774-777.
135. CHAN HL, TANG JL, TAM W, SUNG JJ: The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis. Aliment. Pharmacol. Ther. (2001) 15:1899-1905. A meta-analysis on the efficacy of thymosin in the treatment against HBV.
136. SHAW T, LOCARNINI S: Combination chemotherapy for hepatitis B virus: the final solution? Hepatology (2000) 32:430-432.
137. SANTANTONIO T, ANNA NG, SINISI E et al.: Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study. J. Hepatol. (2002) 36:799-804.
138. SCHIFF ER, DIENSTAG JL, KARAYALCIN S et al.: Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J. Hepatol. (2003) 38:818-826.
139. DIMOU E, ALEXOPOULOU A, PAPADIMITROPOULOS V, PAPATHEODORIDIS GV, HADZIYANNIS SJ: Effect of a 6-month interferon-alfa (IFNα) course on efficacy of long-term lamivudine (LAM) monotherapy in patients with HBeAg-negative [HBeAg (-)] chronic hepatitis B. J. Hepatol. (2003) 38(Suppl. 2):136.
140. MANESIS EK, PAPATHEODORIDIS GV, ALEXOPOULOU A: Treatment of HBeAg-negative chronic hepatitis B (CHBe-) with sequential lamivudine (LAM) and interferon-alfa (IFN) courses of 12-month duration and a 6-month overlap. J. Hepatol, (2003) 38(Suppl. 2):526-527.
141. SCHALM SW, HEATHCOTE J, CIANCIARA J et al.: Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut (2000) 46:562-568.
142. BARBARO G, ZECHINI F, PELLICELLI AM et al.: Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial. J. Hepatol. (2001) 35:406-411.
143. SHARMA BC, SARIN SK, KUMAR S et al.: Higher efficacy of sequential tehrapy of lamivudine and interferon-α (IFN) versus lamivudine monotherapy in patients with HBeAg positive chronic hepatitis B (CHB): a prospective randomized controlled trial. J. Hepatol. (2004) 40(Suppl. 1):131.
144. CHAN HLY, LEUNG NWY, HUI AY et al.: A randomized trial of peginterferon alfa-2b and lamivudine combination treatment versus lamivudine monotherapy in Chinese patients with HBeAg-positive chronic hepatitis B. J. Hepatol. (2004) 40(Suppl. 1):125-126.
145. VAN ZONNEVELD M, HANSEN BE, NIESTERS HGM, DE MAN RA, SCHALM SW, JANSSEN HLA: Viral dynamics during PEG-interferon alone and in combination with lamivudine. J. Hepatol. (2004) 40(Suppl. 1):132.
146. LAU GK, TSIANG M, HOU J et al.: Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study. Hepatology (2000) 32:394-399.
147. SUNG JJY, LAI JY, ZEUZEM S et al.: A randomised double-blind Phase II study of lamivudine (LAM) compared to lamivudine plus adefovir dipivoxil (ADV) for treatment naive patients with chronic hepatitis B (CHB): week 52 analysis. J. Hepatol. (2003) 38(Suppl. 2):25-26.
148. AKBAR SM, FURUKAWA S, HORIIKE N, ONJI M: Vaccine therapy for hepatitis B virus carrier. Curr. Drug Targets Infect. Disord. (2004) 4:93-101.
149. HELVACI M, KIZILGUNESLER A, KASIRGA E, OZBAL E, KUZU M, SOZEN G: Efficacy of hepatitis B vaccination and interferon-alpha-2b combination therapy versus interferon-alpha-2b monotherapy in children with chronic hepatitis B. J. Gastroenterol. Hepatol. (2004) 19:785-791.
150. RASI G, MUTCHNICK MG, DI VIRGILIO D et al.: Combination low-dose lymphoblastoid interferon and thymosin alpha 1 therapy in the treatment of chronic hepatitis B. J. Viral Hepat. (1996) 3:191-196.
151. SARUC M, YUCEYAR H, KUCUKMETIN N, DEMIR MA, KANDILOGLU AR: Combination thymosin-alpha 1 and interferon-alpha 2b in the treatment of anti-HBe-positive chronic hepatitis B in Turkey. Hepatogastroenterology (2002) 49:798-802.
152. LAU GK, NANJI A, HOU J et al.: Thymosin-alpha1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase. J. Viral Hepat. (2002) 9:280-287.
153. SARUC M, OZDEN N, TURKEL N et al.: Long-term outcomes of thymosin-alpha 1 and interferon alpha-2b combination therapy in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B. J. Pharm. Sci. (2003) 92:1386-1395.
154. DAHMEN A, HERZOG-HAUFF S, BOCHER WO, GALLE PR, LOHR HF: Clinical and immunological efficacy of intredermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B. J. Med. Virol. (2002) 66:452-460.
155. MENNE S, RONEKER CA, KORBA BE, GERIN JL, TENNANT BC, COTE PJ: Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection. J. Virol. (2002) 76:5305-5314.
156. MENNE S, RONEKER CA, TENNANT BC, KORBA BE, GERIN JL, COTE PJ: Immunogenic effects of woodchuck hepatitis virus surface antigen vaccine in combination with antiviral therapy: breaking of humoral and cellular immune tolerance in chronic woodchuck hepatitis virus infection. Intervirology (2003) 45:237-250.
157. JACQUARD AC, NASSAL M, PICHOUD C et al.: Effect of a combination of clevudine and emtricitabine with adenovirus-mediated delivery of gamma interferon in the woodchuck model of hepatitis B virus infection. Antimicrob. Agents Chemother. (2004) 48:2683-2692.
158. HEATHCOTE E, MCHUTCHINSON J, LEE S et al.: A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. Hepatology (1999) 30:531-536.
159. DAVIS HL, MICHEL M-L, WHALEN RG: DNA based immunization for hepatitis B induces continuous secretion of antigen and high levels of circulating antibody. Hum. Molec. Genet. (1993) 2:1847-1851.
160. MAILLIARD ME, GOLLAN JL: Suppressing hepatitis B without resistance - so far, so good. N. Engl. J. Med. (2003) 348:848-850.
161. KEEFFE EB, DIETERICH DT, HAN SH et al.: A treatment algorithm for the management ofchronic hepatitis B virus infection in the United States. Clin. Gastroenterol. Hepatol. (2004) 2:87-106.